{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-228130","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.927884+00:00","generated_at":"2026-06-10T23:52:52.435718+00:00","sec_items":["2.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Travere closes $210M asset sale to Mirum; eligible for up to $235M in milestones","bullets":["Upfront cash payment of $210M from Mirum for Chenodal and Cholbam assets.","Potential milestone payments up to $235M based on annual net sales tiers ($125M-$500M).","Transaction closed on August 31, 2023, as previously announced on July 16, 2023.","Pro forma financial statements to be filed by amendment within four business days."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-228130","json":"https://secwatch.observer/filing/0001193125-23-228130.json","markdown":"https://secwatch.observer/filing/0001193125-23-228130.md","text":"https://secwatch.observer/filing/0001193125-23-228130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000119312523228130/0001193125-23-228130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000119312523228130/d548855d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:52:52.435718+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ec65f4aad82f3f59e82bc01ed38d855dc8f79cdc","claim":"Travere Therapeutics, Inc. completed a disposition involving Mirum Pharmaceuticals, Inc. for $210,000,000 (closed 2023-08-31).","evidence_excerpt":"of Chenodal and Cholbam (also known as Kolbam, and together with Chenodal, the “Products”). In connection with the Closing, Mirum paid the Company an upfront cash payment of $210,000,000. Pursuant to the Purchase Agreement, after the Closing, the Company is eligible to receive up to $235,000,000 upon the achievement of certain milestones based on specified","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000119312523228130/0001193125-23-228130-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Mirum Pharmaceuticals, Inc."},{"label":"Consideration","value":"$210,000,000"},{"label":"Closing","value":"2023-08-31"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}